1. Home
  2. FLX vs XOMAP Comparison

FLX vs XOMAP Comparison

Compare FLX & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLX
  • XOMAP
  • Stock Information
  • Founded
  • FLX 2013
  • XOMAP N/A
  • Country
  • FLX China
  • XOMAP United States
  • Employees
  • FLX N/A
  • XOMAP 13
  • Industry
  • FLX
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLX
  • XOMAP Health Care
  • Exchange
  • FLX NYSE
  • XOMAP Nasdaq
  • Market Cap
  • FLX N/A
  • XOMAP N/A
  • IPO Year
  • FLX 2024
  • XOMAP N/A
  • Fundamental
  • Price
  • FLX $2.85
  • XOMAP $25.60
  • Analyst Decision
  • FLX
  • XOMAP
  • Analyst Count
  • FLX 0
  • XOMAP 0
  • Target Price
  • FLX N/A
  • XOMAP N/A
  • AVG Volume (30 Days)
  • FLX 101.7K
  • XOMAP N/A
  • Earning Date
  • FLX 05-22-2025
  • XOMAP N/A
  • Dividend Yield
  • FLX N/A
  • XOMAP N/A
  • EPS Growth
  • FLX N/A
  • XOMAP N/A
  • EPS
  • FLX N/A
  • XOMAP N/A
  • Revenue
  • FLX $595,490,250.00
  • XOMAP N/A
  • Revenue This Year
  • FLX N/A
  • XOMAP N/A
  • Revenue Next Year
  • FLX N/A
  • XOMAP N/A
  • P/E Ratio
  • FLX N/A
  • XOMAP N/A
  • Revenue Growth
  • FLX N/A
  • XOMAP N/A
  • 52 Week Low
  • FLX $2.01
  • XOMAP N/A
  • 52 Week High
  • FLX $21.95
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • FLX N/A
  • XOMAP 47.92
  • Support Level
  • FLX N/A
  • XOMAP $25.65
  • Resistance Level
  • FLX N/A
  • XOMAP $25.70
  • Average True Range (ATR)
  • FLX 0.00
  • XOMAP 0.06
  • MACD
  • FLX 0.00
  • XOMAP -0.00
  • Stochastic Oscillator
  • FLX 0.00
  • XOMAP 22.85

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: